European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes

Journal of Clinical Microbiology

Volumn 44, Issue 8, 2006, Pages 2792-2800

  Tran, N ^a   Berne, R ^a   Chann, R ^a   Gauthier, M ^a   Martin, D ^a   Armand, M A ^a   Ollivet, A ^b   Teo, C G ^c   Ijaz, S ^c   Flichman, D ^d   Brunetto, M ^d   Bielawski, K P ^e   Pichoud, C ^b   Zoulim, F ^b   Vernet, G ^a  

^a BIOMÉRIEUX   (France)

^b INSERM   (France)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Azienda Ospedaliera   (Italy)

^e UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

POL PROTEIN; PROTEIN S; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CODON; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DNA PROBE; DRUG SENSITIVITY; EVALUATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPRODUCIBILITY; VACCINATION; VIRUS GENOME; VIRUS MUTATION; VIRUS RESISTANCE;

DNA, VIRAL; DRUG RESISTANCE, VIRAL; EUROPE; GENE PRODUCTS, POL; GENOME, VIRAL; GENOTYPE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; STATISTICS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 33747153395     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00295-06     Document Type: Article

References (38)

1. Aberle, S. W., J. Kletzmayr, B. Watschnger, B. Schmied, N. Vetter, and E. Puchhammer-Stöckl. 2001. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J. Clin. Microbiol. 39:1972-1974.
2. Asselah, T., M.-P. Ripault, C. Castelnau, N. Giuily, N. Boyer, and P. Marcellin. 2005. The current status of antiviral therapy of chronic hepatitis B. J. Clin. Virol. 34(Suppl. 1):S115-S124.
3. Baptista, M., A. Kramvis, and M. C. Kew. 1999. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 29:946-953.
4. Bartholomeusz, A., B. G. Tehan, and D. K. Chalmers. 2004. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 9:149-160.
5. Basuni, A. A., and W. F. Carman. 2004. HBV vaccine-escape variants. Methods Mol. Med. 95:115-124.
6. Bernal-Mendez, E., C. Tora, I. Sothier, M. Kotera, A. Troesch, and A. Laayoun. 2003. Universal labeling chemistry for nucleic acid detection on DNA-arrays. Nucleosides Nucleotides Nucleic Acids 22:1647-1649.
7. Brunelle, M.-N., A.-C. Jacquard, C. Pichoud, D. Durantel, S. Carrouée-Durantel, J.-P. Villeneuve, C. Trépo, and F. Zoulim. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
8. Brunetto, M. R., M. Stemler, F. Schodel, H. Will, A. Ottobrelli, M. Rizzetto, G. Verne, and F. Bonino. 1989. Identification of HBV variants which cannot produce precore derived HBcAg and may be responsible for severe hepatitis. Ital. J. Gastroenterol. 21:151-154.
9. Brunetto, M. R., E. Giarin, F. Oliveri, E. Chiaberge, M. Baldi, A. Alfarano, A. Serra, G. Saracco, G. Verme, H. Will, and F. Bonino. 1991. Wild-type and e antigen-minus hepatitis viruses and course of chronic hepatitis Proc. Natl. Acad. Sci. USA 88:4186-4190.
10. Brunetto, M. R., M. Giarin, G. Saracco, F. Oliveri, P. L. Calvo, G. Capra, A. Randone, M. L. Abate, P. Manzini, M. Capalbo, P. Piantino, G. Verme, and F. Bonino. 1993. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105:845-850.
11. Buti, M., F. Rodriguez-Frias, R. Jardi, and R. Esteban. 2005. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J. Clin. Virol. 34(Suppl. 1):S79-S82.
12. Carman, W. F., M. R. Jacyna, S. Hadziyannis, P. Karayiannis, M. J. McGarvey, A. Makris, and H. C. Thomas. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii:588-591.
13. Carman, W. F., A. R. Zanetti, P. Karayiannis, J. Waters, G. Manzillo, E. Tanzi, A. J. Zuckerman, and H. C. Thomas. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
14. Chu, C. J., M. Hussain, and A. S. Lok. 2002. Hepatitis B virus genotype B is associated with earlier HbeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122:1756-1762.
15. Department of Health and Human Services. 2005. Guidelines for the use of antiretroviral agents in HIV-1-infected adolescents and adults. Office of AIDS Research Advisory Council, Department of Health and Human Services, Washington, D.C. [Online.] http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
16. Durantel, D., M.-N. Brunelle, E. Gros, S. Carrouée-Durantel, C. Pichoud, S. Villet, C. Trépo, and F. Zoulim. 2005. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J. Clin. Virol. 34(Suppl. 1):S34-S43.
17. Fortuin, M., V. Karthigesu, L. Allison, C. Howard, S. Hoare, M. Mendy, and H. C. Whittle. 1994. Breakthrough infections and identification of a novel variant in Gambian children immunized with hepatitis B vaccine. J. Infect. Dis. 169:1374-1376.
18. Hsu, H. Y., M. H. Chang, Y. H. Ni, H. H. Lin, S. M. Wang, and D. S. Chen. 1997. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26:786-791.
19. Hsu, H. Y., M. H. Chang, Y. H. Ni, and H. L. Chen. 2004. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53:1499-1503.
20. INVS. 2005. Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l'hépatite B chez les assurés sociaux du régime général de France métropolitaine 2003-2004. [Online.] http://www.invs.sante.fr/ publications/2005/analyse_descriptive_140205/rapport_analyse_descriptive.pdf.
21. Ishikawa, K., T. Koyama, and T. Masuda. 2002. Prevalence of HBV genotypes in asymptomatic carrier residents and their clinical characteristics during long-term follow-up: the relevance to changes in the HBeAg/anti-HBe system. Hepatol. Res. 24:1.
22. Jang, H., M. Cho, J. Heo, H. Kim, H. Jun, W. Shin, B. Cho, H. Park, and C. Kim. 2004. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42:4181-4188.
23. Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559.
24. Lavanchy, D. 2005. Worldwide epidemiology of HBV infection, disease burden and vaccine prevention. J. Clin. Virol. 34(Suppl. 1):S1-S3.
25. Lee, C. M., C. H. Chen, S. N. Lu, H. D. Tung, W. J. Chou, J. H. Wang, T. M. Chen, C. H. Hung, C. C. Huang, and W. J. Chen. 2003. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand. J. Gastroenterol. 38:95-101.
26. Lok, A. S. F., F. Zoulim, S. Locarnini, A. Mangia, G. Niro, H. Decraemer, G. Maertens, F. Hulstaert, K. De Vreese, and E. Sablon. 2002. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40:3729-3734.
27. Norder, H., A.-M. Couroucé, P. Coursaget, J.-M. Echevarria, S. D. Lee, I. K. Mushahwar, B. H. Robertson, S. Locarnini, and L. O. Magnius. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289-309.
28. Ogata, N., R. H. Miller, K. G. Ishak, and R. H. Purcell. 1993. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 194:263-276.
29. Pas, S. D., R. A. de Man, E. Fries, A. B. van Nunen, A. D. M. E. Osterhaus, and H. G. M. Niesters. 2002. The dynamics of mutations in the polymerase gene of hepatitis B virus during and after lamivudine treatment. J. Clin. Virol. 25:63-71.
30. Pawlotsky, J.-M. 2005. The concept of hepatitis B virus mutant escape. J. Clin. Virol. 34(Suppl. 1):S125-S129.
31. Sato, S., K. Suzuki, Y. Akahane, K. Akamatsu, K. Akiyama, K. Yunomura, F. Tsuda, T. Tanaka, H. Okamoto, Y. Miyakawa, and M. Mayumi. 1995. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann. Intern. Med. 122:241-248.
32. Sirma, H., C. Giannini, K. Poussin, P. Paterlini, D. Kremsdorf, and C. Brechot. 1999. Hepatitis B virus, X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene. 18:4848-4859.
33. Sugauchi, F., A. Chutaputti, E. Onto, H. Kato, S. Suzuki, R. Ueda, and M. Mizokami. 2002. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. J. Gastroenterol. Hepatol. 17:671-676.
34. Sumi, H., O. Yokosuda, N. Seki, M. Arai, F. Imazeki, T. Kurihara, T. Kanda, K. Fukai, M. Kato, and H. Saiso. 2003. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37:19-26.
35. Thakur, V., R. C. Guptan, S. N. Kazim, V. Malhotra, and S. K. Sarin. 2002. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J. Gastroenterol. Hepatol. 17:165-170.
36. Tu, H., C. Bonura, C. Giannini, H. Mouly, P. Soussan, M. Kew, P. Paterlini-Brechot, C. Brechot, and D. Kremsdorf. 2001. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 61:7803-7810.
37. Zollner, B., J. Petersen, M. Schroter, R. Laufs, V. Schoder, and H. H. Feucht. 2001. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 57:934-935.
38. Zollner, B., J. Petersen, E. Puchhammer-Stockl, J. Kletzmayr, M. Sterneck, L. Fischer, M. Schroter, R. Laufs, and H. H. Feucht. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 9:42-50.